Cancer Treatment
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Unlock global cancer treatment market insights. Stay ahead on drug approvals, clinical trials, and therapeutic advancements for pharma investors & BD.
Showing 1–12 of 21 articles
Quick answer
NovaPharmaNews Cancer Treatment hub for FDA covers 21 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
New Radiopharmaceutical Shows Promise in Post-Pluvicto Setting, Offering Competitive Insights
HER2 Biology's Role in Advancing Next-Generation Cancer Therapies
Regeneron Pharma Stock Surges: Fresh Institutional Buying Insights
NICE Approval for Imfinzi: Implications for Stomach Cancer Treatment
THMA Oncology Forum: Key Insights and Discussions Day 1
XtalPi-Enabled PEP08 PRMT5 Inhibitor Begins Phase I Cancer Trial Enrollment
ANVISA Clinical Trial Changes Brazil: What You Need to Know
Arvinas Receives FDA Approval for VEPPANU (Vepdegestrant), First PROTAC Drug for ESR1-Mutated Breast Cancer
FDA Companion Diagnostic Policies: Market Evolution in Precision Oncology
FDA Accelerated Approvals Oncology: 2026 Review of Benefit-Risk and Confirmatory Trials
Pembrolizumab FDA Approval: Expanded Use for MSI-High Solid Tumors
Sun Pharma Acquires Organon for $11.75 Billion in Major Pharmaceutical Merger
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.